Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qiang Chi

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Cell Research|August 2, 2007
Expression changes of hippocampal energy metabolism enzymes contribute to behavioural abnormalities during chronic morphine treatmentXiao-Lan Chen, Gang Lu, Ying-Xia Gong, et al.
Journal of Neurochemistry|November 19, 2008
Role of Src in ligand-specific regulation of delta-opioid receptor desensitization and internalizationMin-Hua Hong, Chi Xu, Yu-Jun Wang, et al.
Journal of Cancer Research and Clinical Oncology|January 22, 2015
Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in ChineseJie Ge, Lin Zhu, Junde Zhou, et al.
Neuropharmacology|April 24, 2016
κ Opioid receptor activation in different brain regions differentially modulates anxiety-related behaviors in miceYu-Jun Wang, Ai Hang, Yu-Chen Lu, et al.
Gut and Liver|January 3, 2018
Methylation Status of Transcriptional Modulatory Genes Associated with Colorectal Cancer in Northeast ChinaHan-Lu Gao, Xuan Wang, Hong-Ru Sun, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 13, 2009
Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behaviorYu-Jun Wang, Yi-Min Tao, Fu-Ying Li, et al.
Acta Pharmacologica Sinica|November 25, 2010
Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in miceJian-feng SUN, Yu-hua WANG, Fu-ying LI, et al.
Nature Communications|November 27, 2025
Quantum light sources with configurable lifetime leveraging parity-time symmetryNuo Chen, Wen-Xiu Li, Yun-Ru Fan, et al.
European Journal of Pharmacology|July 8, 2014
Pharmacological characterization and therapeutic potential for the treatment of opioid abuse with ATPM-ET, an N-ethyl substituted aminothiazolomorphinan with κ agonist and μ agonist/antagonist activityJian-Feng Sun, Yu-Hua Wang, Jing-Rui Chai, et al.
Journal of Cell Science|November 25, 2010
Serine 363 of the {delta}-opioid receptor is crucial for adopting distinct pathways to activate ERK1/2 in response to stimulation with different ligandsChi Xu, Min-Hua Hong, Le-Sha Zhang, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Cell Research|August 2, 2007
Expression changes of hippocampal energy metabolism enzymes contribute to behavioural abnormalities during chronic morphine treatmentXiao-Lan Chen, Gang Lu, Ying-Xia Gong, et al.
Journal of Neurochemistry|November 19, 2008
Role of Src in ligand-specific regulation of delta-opioid receptor desensitization and internalizationMin-Hua Hong, Chi Xu, Yu-Jun Wang, et al.
Journal of Cancer Research and Clinical Oncology|January 22, 2015
Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in ChineseJie Ge, Lin Zhu, Junde Zhou, et al.
Neuropharmacology|April 24, 2016
κ Opioid receptor activation in different brain regions differentially modulates anxiety-related behaviors in miceYu-Jun Wang, Ai Hang, Yu-Chen Lu, et al.
Gut and Liver|January 3, 2018
Methylation Status of Transcriptional Modulatory Genes Associated with Colorectal Cancer in Northeast ChinaHan-Lu Gao, Xuan Wang, Hong-Ru Sun, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 13, 2009
Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behaviorYu-Jun Wang, Yi-Min Tao, Fu-Ying Li, et al.
Acta Pharmacologica Sinica|November 25, 2010
Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in miceJian-feng SUN, Yu-hua WANG, Fu-ying LI, et al.
Nature Communications|November 27, 2025
Quantum light sources with configurable lifetime leveraging parity-time symmetryNuo Chen, Wen-Xiu Li, Yun-Ru Fan, et al.
European Journal of Pharmacology|July 8, 2014
Pharmacological characterization and therapeutic potential for the treatment of opioid abuse with ATPM-ET, an N-ethyl substituted aminothiazolomorphinan with κ agonist and μ agonist/antagonist activityJian-Feng Sun, Yu-Hua Wang, Jing-Rui Chai, et al.
Journal of Cell Science|November 25, 2010
Serine 363 of the {delta}-opioid receptor is crucial for adopting distinct pathways to activate ERK1/2 in response to stimulation with different ligandsChi Xu, Min-Hua Hong, Le-Sha Zhang, et al.
Pageof 10